Celcuity Inc. (CELC) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "CELC"
      ],
      "issuer_cik": "0001603454",
      "owner_cik": "0001087940",
      "accession_number": "0001193125-26-306299",
      "form_type": "4",
      "filing_date": "2026-07-16",
      "period_of_report": "2026-07-14",
      "issuer_name": "Celcuity Inc.",
      "issuer_trading_symbol": "CELC",
      "owner_name": "BAKER FELIX",
      "is_director": false,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": true,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-07-14",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 261368,
      "transaction_price_per_share": 102.5,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 442940,
      "transaction_value": 26790220,
      "not_subject_to_section_16": true,
      "direct_or_indirect": "I",
      "nature_of_ownership": "See Footnotes",
      "footnotes": [
        {
          "id": "F1",
          "description": "After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. (\"667\"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock (\"Common Stock\") of Celcuity Inc. (the \"Issuer\") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."
        },
        {
          "id": "F2",
          "description": "Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."
        },
        {
          "id": "F3",
          "description": "Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."
        }
      ],
      "remarks": "On July 14, 2026, Baker Bros. Advisors LP on behalf of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"), submitted written notice to Celcuity Inc. (the \"Issuer\") to set the beneficial ownership limitation (the \"Maximum Percentage\") with respect to 481,437 and 5,666,350 prefunded warrants to purchase common stock of the Issuer (\"Common Stock\") at an exercise price of $0.001 per share held by 667 and Life Sciences, respectively, at 9.99%.  As a result of the transactions reported herein and the setting of the Maximum Percentage at 9.99%, the reporting persons no longer beneficially own greater than 10% of the Common Stock."
    },
    {
      "tickers": [
        "CELC"
      ],
      "issuer_cik": "0001603454",
      "owner_cik": "0001087939",
      "accession_number": "0001193125-26-306299",
      "form_type": "4",
      "filing_date": "2026-07-16",
      "period_of_report": "2026-07-14",
      "issuer_name": "Celcuity Inc.",
      "issuer_trading_symbol": "CELC",
      "owner_name": "BAKER JULIAN",
      "is_director": false,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": true,
      "security_type": "non_derivative",
      "record_type": "transaction",
      "security_title": "Common Stock",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-07-14",
      "transaction_code": "S",
      "equity_swap_involved": false,
      "transaction_shares": 261368,
      "transaction_price_per_share": 102.5,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 442940,
      "transaction_value": 26790220,
      "not_subject_to_section_16": true,
      "direct_or_indirect": "I",
      "nature_of_ownership": "See Footnotes",
      "footnotes": [
        {
          "id": "F1",
          "description": "After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. (\"667\"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock (\"Common Stock\") of Celcuity Inc. (the \"Issuer\") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."
        },
        {
          "id": "F2",
          "description": "Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. (\"Life Sciences\" and together with 667, the \"Funds\"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."
        },
        {
          "id": "F3",
          "description": "Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."
        }
      ],
      "remarks": "On July 14, 2026, Baker Bros. Advisors LP on behalf of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\"), submitted written notice to Celcuity Inc. (the \"Issuer\") to set the beneficial ownership limitation (the \"Maximum Percentage\") with respect to 481,437 and 5,666,350 prefunded warrants to purchase common stock of the Issuer (\"Common Stock\") at an exercise price of $0.001 per share held by 667 and Life Sciences, respectively, at 9.99%.  As a result of the transactions reported herein and the setting of the Maximum Percentage at 9.99%, the reporting persons no longer beneficially own greater than 10% of the Common Stock."
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.